PO-REN HSUEHLau Y.-J.Ko W.-C.Liu C.-Y.Huang C.-T.Yen M.-Y.Liu Y.-C.Lee W.-S.Liao C.-H.Peng M.-Y.Chen C.-M.Chen Y.-S.2020-12-182020-12-1820111684-1182https://scholars.lib.ntu.edu.tw/handle/123456789/528543[SDGs]SDG3ciprofloxacin; cotrimoxazole; levofloxacin; lomefloxacin; norfloxacin; ofloxacin; quinoline derived antiinfective agent; acute pyelonephritis; antibiotic resistance; antibiotic sensitivity; antibiotic therapy; article; bacteremia; bactericidal activity; communicable disease; consensus; drug megadose; drug urine level; Enterobacteriaceae; Escherichia coli; human; minimum inhibitory concentration; Pseudomonas aeruginosa; risk factor; Staphylococcus; Taiwan; urinary tract infection; Anti-Bacterial Agents; Consensus Development Conferences as Topic; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Urinary Tract Infectionsjournal article10.1016/j.jmii.2011.01.015214395072-s2.0-79952897857